Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.09 -0.21 (-0.74%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Got $1,000? 2 Healthcare Stocks to Buy and Hold Forever.
These two stocks have moved in different directions this year, but that shouldn't mean much to long-term investors. 
Via The Motley Fool
3 Sweet Dividend Stocks to Treat Your Portfolio With This Halloween
There are more reasons to buy these stocks besides their high payouts. 
Via The Motley Fool
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for millions at risk of serious disease. 
Via Benzinga
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines
The CDC recommends expanding pneumococcal vaccine eligibility to adults aged 50 and above, impacting disease prevention with Pfizer and Merck's vaccines. 
Via Benzinga
5 High-Yield Dividend Stocks to Buy Without Hesitation
These five dividend powerhouses offer yields above 4%. 
Via The Motley Fool
Key Takeaways From Pfizer Analyst Ratings
Via Benzinga
A Closer Look at Pfizer's Options Market Dynamics
Via Benzinga
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. 
Via Benzinga
Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
From Pfizer Inc.
Via Business Wire
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals to safeguard infants from birth. 
Via Benzinga
Exposures Product Safety
The Best Pharmaceutical Stock to Invest $1,000 in Right Now
Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns. 
Via The Motley Fool
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
From Pfizer Inc.
Via Business Wire
Activist Investor Starboard Slams Pfizer for Underperforming R&D And Overpaying for Acquisitions
Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets since the COVID-19 boom. 
Via Benzinga
Exposures COVID-19
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Viking Therapeutics (VKTX) set to report Q3 earnings amid high expectations, thanks to promising weight-loss drug candidate. Stock up 240% YTD. 
Via Benzinga
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
The activist investor says Pfizer has underperformed its peers and the broader market since 2019. 
Via Investor's Business Daily
Do Billionaires Israel Englander and Ken Griffin Know Something? Each Just Bought This Plagued Value Stock.
Hedge funds managed by Israel Englander and Ken Griffin both scooped up shares in a troubled pharmaceutical stock last quarter. 
Via The Motley Fool
Nvidia Among Five Best S&P 500 Stocks Today
Pfizer spinoff Kenvue led the S&P 500 on Monday. Nvidia was close behind. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Three AI Stocks That Could Beat Nvidia After Today
Nvidia has returned 700% during the Age of AI, but smaller companies may have more room to run. Pfizer, Tesla, and Kroger are potential AI stocks. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
1 Ultra-High-Yield Healthcare Stock to Buy Hand Over Fist and 1 to Avoid
Income investors have both good and not-so-good options in the healthcare sector. 
Via The Motley Fool
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Yes, bargains can still be found in the stock market. 
Via The Motley Fool
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now
These stocks could deliver big over the long term. 
Via The Motley Fool
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle technology without permission in the development of its COVID-19 vaccines. 
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Guggenheim's Longstanding Pfizer Ties Tested Amid Starboard Battle
Guggenheim finds itself in the middle of a battle between Pfizer and Starboard Value as activist investors push for change amid declining stock performance and costly acquisitions. 
Via Benzinga
Why I'm Considering Leaning Heavily Into Pfizer
Pfizer's high dividend yield and robust pipeline could offer significant returns for patient investors. 
Via The Motley Fool
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks royalties for Moderna's alleged unlicensed use of its groundbreaking vaccine... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Tim Buckley Elected to Pfizer’s Board of Directors
From Pfizer Inc.
Via Business Wire
Pfizer Is Clashing With Its New Activist Investor. Will It Harm The Stock?
This investor's campaign is stoking some undesirable corporate intrigue. 
Via The Motley Fool
2 Ultra-High-Yield Dividend Stocks With Total Return Potential of Up to 92% in 12 Months, According to Select Wall Street Analysts
Two supercharged income stocks -- sporting yields of 5.6% and 5.8% -- have the tools and intangibles needed to catapult higher. 
Via The Motley Fool
The Bull's Biggest Hits And Misses
The bull market turned two years old over the weekend. Here are some of the S&P 500's biggest winners and losers over the last two years. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.